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Abstract. An exome-wide association study (EWAS) 
was performed to identify genetic variants, particularly 
low-frequency or rare coding variants with a moderate to 
large effect size, that confer susceptibility to atrial fibrillation 
in Japanese. The EWAS for atrial fibrillation was performed 
with 13,166 subjects (884 patients with atrial fibrillation and 
12,282 controls) using an Illumina HumanExome-12 DNA 
Analysis BeadChip or Infinium Exome‑24 BeadChip arrays. 
The association of atrial fibrillation with allele frequencies of 
41,243 single nucleotide polymorphisms (SNPs) that passed 
quality control was examined with Fisher's exact test. Based on 
Bonferroni's correction, a P<1.21x10-6 was considered statisti-
cally significant. The EWAS for atrial fibrillation revealed that 
122 SNPs were significantly associated with this condition. 
The association of the identified SNPs to atrial fibrillation was 
further examined by multivariable logistic regression analysis 
with adjustment for age, sex and the prevalence of hyperten-
sion. Eight SNPs were related (P<0.01) to atrial fibrillation, 
among which three polymorphisms, rs11552708 [G/A (G67R)]
of TNF superfamily member 13 (TNFSF13; dominant model; 
P=9.36x10-9; odds ratio, 0.58), rs113710653 [C/T (E231 K)] of 
spermatogenesis and centriole associated 1 like (SPATC1L; 
dominant model; P=1.09x10-5; odds ratio, 3.27), and 
rs11231397 [G/C (R300T)] of solute carrier family 22 member 
25 (SLC22A25; additive model; P=3.71x10-5; odds ratio, 1.77), 
were significantly (P<1.02x10-4) associated with this condi-
tion. The minor T allele of rs113710653 and the minor C allele 
of rs11231397 were risk factors for atrial fibrillation, whereas 
the minor A allele of rs11552708 was protective against this 
condition. In addition, rs77538589 [C/T (G117R)] of SALL4 
exhibited a tendency to be associated with atrial fibrillation 
(dominant model; P=0.0002; odds ratio, 1.88), with the minor 
T allele representing a risk factor for this condition. TNFSF13, 
SPATC1L, SLC22A25 and SALL4 may thus be novel suscep-
tibility loci for atrial fibrillation in the Japanese population.
Introduction
Atrial fibrillation (AF) is the most common type of cardiac 
arrhythmia and a major public health problem. The estimated 
number of individuals with AF worldwide was 33.5 million in 
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2010 (1). The prevalence of AF is increasing and is estimated 
to double in the United States by 2050 (2). AF is associated 
with an increased risk of heart failure, thromboembolic 
diseases, such as cardioembolic stroke, and mortality (3). 
Although the molecular mechanism underlying AF is complex 
and has not been determined definitively, several risk factors, 
including age, smoking, obesity, hypertension, diabetes 
mellitus, valvular heart disease, coronary artery disease and 
heart failure, have been identified clinically (4). In addition to 
these conventional risk factors, recent studies have reported 
the importance of genetic factors in the development of AF (5). 
Genome-wide association studies (GWASs) and subsequent 
meta‑analyses of such studies have identified several genes and 
loci that confer susceptibility to AF in populations of European 
ancestry (6-10). However, susceptibility genes for AF have not 
been determined definitively in Japanese populations.
The majority of genetic variants previously reported to 
be associated with AF have a minor allele frequency (MAF) 
of ≥5% and a small individual effect size. Given that these 
common variants explain only a fraction of the heritability of 
AF, it is likely that low‑frequency (0.5%≤ MAF <5%) or rare 
(MAF <0.5%) variants with larger effect sizes contribute to 
the genetic architecture of AF (11).
An exome-wide association study (EWAS) with exome 
array-based genotyping was performed to identify single 
nucleotide polymorphisms (SNPs), especially low-frequency 
or rare coding variants with moderate to large effect sizes, 
that confer susceptibility to AF in Japanese individuals. Given 
that GWAS arrays of previous studies did not include most 
low-frequency or rare variants, Illumina human arrays that 
cover functional SNPs in entire exons including such variants 
were used in the current study.
Materials and methods
Study subjects. A total of 13,166 Japanese individuals 
(884 patients with AF and 12,282 controls) were examined. 
The subjects were recruited either from individuals who 
visited outpatient clinics of or were admitted to participating 
hospitals (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu 
Prefectural General Medical Center, Gifu; Japanese Red 
Cross Nagoya First Hospital, Nagoya; Inabe General Hospital, 
Inabe; Hirosaki University Hospital and Hirosaki Stroke and 
Rehabilitation Center, Hirosaki, Japan) because of various 
symptoms or for an annual health checkup between 2002 and 
2014; from community-dwelling individuals recruited to a 
population-based cohort study in Inabe between 2010 and 2014 
(Health Care Center of Inabe General Hospital) or in Tokyo or 
Kusatsu between 2011 and 2015 (Tokyo Metropolitan Institute 
of Gerontology); or from cases of autopsy performed at the 
Tokyo Metropolitan Geriatric Hospital from 1995 to 2012.
Individuals with persistent or paroxysmal AF or with a 
history of AF were included in the AF patient group regard-
less of medical treatment. Patients with AF who had severe 
valvular heart disease, hypertrophic or dilated cardiomy-
opathy, or congenital heart disease were excluded from the 
study. The control individuals had no history of AF or other 
significant supraventricular or ventricular arrhythmias or of 
taking antiarrhythmic medication. Autopsy cases were not 
used as controls.
The study protocol complied with the Declaration of 
Helsinki and was approved by the Committees on the Ethics 
of Human Research of Mie University Graduate School of 
Medicine (Tsu, Japan), Hirosaki University Graduate School 
of Medicine (Hirosaki, Japan), Tokyo Metropolitan Institute 
of Gerontology (Tokyo, Japan) and participating hospitals. 
Written informed consent was obtained from each participant 
or families of the deceased subjects.
EWAS. Venous blood (5-7 ml) was collected into tubes containing 
50 mmol/l ethylenediaminetetraacetic acid (disodium salt), 
peripheral blood leukocytes were isolated, and genomic DNA 
was extracted from the cells with the use of a DNA extraction 
kit (Genomix supplied by Talent Srl, Trieste, Italy; or SMITEST 
EX-R&D supplied by Medical & Biological Laboratories, 
Co., Ltd., Nagoya, Japan) or by standard protocols based on 
phenol-chloroform extraction and spin columns. Lysed blood 
cells were mixed with an equal volume of a phenol-chloroform 
mixture. Following centrifugation at 16,000 x g for 5 min at 
room temperature, two distinct phases were formed. The upper 
aqueous phase was collected, and genomic DNA was further 
purified by a spin column-based DNA extraction method 
that is based on the fact that DNA binds to the solid phase of 
silica under certain conditions. A buffer solution (Buffer B3; 
Takara Bio, Inc., Otsu, Japan) was added to the DNA sample 
along with 100% ethanol. This solution was transferred to a 
spin column, and the column was centrifuged at 11,000 x g for 
1 min at room temperature. A wash buffer [Buffer BW (first 
wash) or Buffer B5 (second wash); Takara Bio, Inc.] was added 
to the column, and the column was centrifuged at 11,000 x g 
for 1 min at room temperature again. An elution buffer (Buffer 
BE; Takara Bio, Inc.) was added to the column, and the column 
was centrifuged at 11,000 x g for 1 min at room temperature 
again. Genomic DNA was collected from the bottom of the 
column. In autopsy cases, genomic DNA was extracted from 
kidneys. The EWAS was performed for 884 subjects with AF and 
12,282 control individuals with the use of a HumanExome-12 
v1.1 or v1.2 DNA Analysis BeadChip or Infinium Exome‑24 v1.0 
BeadChip (Illumina, Inc., San Diego, CA, USA). These exome 
arrays include putative functional exonic variants selected 
from >12,000 individual exome or whole-genome sequences. 
The exonic content consists of ~244,000 SNPs representing 
diverse populations, including European, African, Chinese and 
Hispanic individuals (12). SNPs contained in only one of the 
exome arrays (~3.6%) were excluded from analysis. Quality 
control (13) was performed as follows: i) Genotyping data with a 
call rate of <97% were discarded, with the mean call rate for the 
remaining data at 99.9%; ii) gender specification was checked 
for all samples, and those for which gender in the clinical records 
was inconsistent with genetic sex were discarded; iii) duplicate 
samples and cryptic relatedness were checked by calculation of 
identity by descent, all pairs of DNA samples with identity by 
descent of >0.1875 were inspected and one sample from each 
pair was excluded; iv) the frequency of SNP heterozygosity was 
calculated for all samples, and those with extremely low or high 
heterozygosity (>3 standard deviations from the mean) were 
discarded; v) SNPs in sex chromosomes or mitochondrial DNA 
were excluded from the analysis, as were nonpolymorphic SNPs 
or SNPs with a MAF of <0.1%; vi) SNPs whose genotype distri-
butions deviated significantly (P<0.001) from Hardy‑Weinberg 
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equilibrium in control individuals were discarded; vii) the 
genotype data for the EWAS were examined for population 
stratification by principal components analysis (14), and popula-
tion outliers were excluded from the analysis. A total of 41,243 
SNPs passed quality control and was subjected to analysis.
Statistical analysis. For analysis of characteristics of the study 
subjects, quantitative data were compared between patients 
with AF and control individuals with the unpaired Student's 
t test. Categorical data were compared between the two groups 
with Fisher's exact test. Allele frequencies were estimated by 
the gene counting method, and Fisher's exact test was applied to 
identify departure from Hardy-Weinberg equilibrium. Allele 
frequencies of SNPs were compared between subjects with AF 
and controls with Fisher's exact test in the EWAS. Multivariable 
logistic regression analysis was performed with AF as a depen-
dent variable and independent variables including age, sex 
(0, woman; 1, man), the prevalence of hypertension (0, no history 
of this condition; 1, positive history), and genotype of each 
SNP. Genotypes of SNPs were assessed according to dominant 
[0, AA; 1, AB+BB (A, major allele; B, minor allele)], recessive 
(0, AA+AB; 1, BB), and additive genetic models, and the 
P‑value, odds ratio, and 95% confidence interval were calcu-
lated. Additive models comprised additive 1 (0, AA; 1, AB; 0, 
BB) and additive 2 (0, AA; 0, AB; 1, BB) scenarios, which were 
analyzed simultaneously with a single statistical model. The 
relation of SNPs to the prevalence of intermediate phenotypes 
of AF was compared among genotypes with Fisher's exact 
test (2x2) or Pearson's chi-square test (2x3). To compensate 
for multiple comparisons of genotypes with AF, we applied 
Bonferroni's correction for statistical significance of associa-
tion. Given that 41,243 SNPs were analyzed, the significance 
level was set at P<1.21x10-6 (0.05/41,243) for the EWAS. A 
quantile-quantile plot for P-values of allele frequencies in 
the EWAS for AF is shown in Fig. 1. The inflation factor (λ) 
was 1.52. Bonferroni's correction was also applied to other 
statistical comparisons as indicated. Statistical tests were 
performed with JMP Genomics version 6.0 software (SAS 
Institute, Inc., Cary, NC, USA).
Results
Characteristics of the study subjects. The characteristics of the 
subjects enrolled in the study are presented in Table I. Age, the 
number of men, and the prevalence of hypertension, diabetes 
mellitus, chronic kidney disease and hyperuricemia were 
significantly greater in patients with AF than in control subjects.
EWAS of AF. The association of AF with allele frequencies of 
41,243 SNPs that passed quality control was determined using 
Fisher's exact test. A Manhattan plot for the EWAS of AF is 
presented in Fig. 2. Following Bonferroni's correction, 122 
SNPs were significantly [P<1.21x10-6 (0.05/41,243)] associated 
with AF (Table II). The genotype distributions of these SNPs 
were in Hardy-Weinberg equilibrium (P>0.001) both among 
subjects with AF and among control individuals (data not 
shown).
Figure 1. Quantile‑quantile plot for P‑values of allele frequencies in the 
exome‑wide association study of atrial fibrillation. The observed P‑values 
(y-axis) were compared with the expected P-values (x-axis) under the null 
hypothesis, with points plotted actually corresponding to the negative 
log-transformed P-values [-log10 (P-values)].
Table I. Characteristics of the 13,166 study subjects.
Characteristic Atrial fibrillation Control P‑value
No. of subjects 884 12,282 
Age (years) 75.8±12.3 59.4±13.2 <0.0001
Sex (male/female, %) 67.8/32.2 56.8/43.2 <0.0001
Body mass index (kg/m2) 23.4±3.7 23.3±3.5 0.7412
Current or former smoker (%) 33.6 36.3 0.2576
Hypertension (%) 83.9 51.1 <0.0001
Diabetes mellitus (%) 51 23.2 <0.0001
Dyslipidemia (%) 65.3 62 0.188
Chronic kidney disease (%) 40.3 23 <0.0001
Hyperuricemia (%) 31.9 17 <0.0001
Quantitative data are presented as the mean ± standard deviation and were compared between patients with atrial fibrillation and control 
individuals using the unpaired Student's t test. Categorical data were compared between the two groups using Fisher's exact test. Based on 
Bonferroni's correction, P<0.0056 (0.05/9) was considered to indicate a statistically significant difference.
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Multivariable logistic regression analysis of the relation of 
SNPs to AF. The association of AF with 122 SNPs identi-
fied by the EWAS was further examined by multivariable 
logistic regression analysis with adjustment for age, sex and 
the prevalence of hypertension. Eight SNPs were identified to 
be associated with AF (P<0.01 in at least one genetic model; 
Table III). Among these eight SNPs, rs11552708 [G/A (G67R)] 
of TNF superfamily member 13 (TNFSF13), rs113710653 
[C/T (E231 K)] of spermatogenesis and centriole associated 
1 like (SPATC1L), and rs11231397 [G/C (R300T)] of solute 
carrier family 22 member 25 (SLC22A25) were significantly 
[P<1.02x10-4 (0.05/488)] associated with AF. The minor 
T allele of rs113710653 and the minor C allele of rs11231397 
were risk factors for AF, whereas the minor A allele of 
rs11552708 was protective against this condition (Table III). In 
addition, the association of rs77538589 [C/T (G117R)] of spalt 
like transcription factor 4 (SALL4) with AF almost achieved 
significance, with the minor T allele representing a risk factor 
for this condition.
Association of SNPs with intermediate phenotypes of AF. 
The association of the four SNPs, rs11552708, rs113710653, 
rs11231397 and rs77538589, with intermediate phenotypes 
of AF was examined. The rs11552708 SNP was significantly 
associated with hyperuricemia [P<0.0016 (0.05/32); Table IV].
Association of genes and SNPs identified in the present study 
with phenotypes previously examined in GWASs. The associa-
tion of the four genes and four SNPs identified in the present 
study with phenotypes previously examined in GWASs 
available in public databases [GWAS Catalog (http://www 
.ebi.ac.uk/gwas) and GWAS Central (http://www.gwascentral 
.org/browser)] was determined. None of the genes or SNPs 
were identified to be associated with AF in previous studies 
(data not shown).
Discussion
The development of AF has been reported to be associated 
with endothelial dysfunction, including the upregulation of 
adhesion molecules, and increased inflammation and oxidative 
stress (15). Such endothelial dysfunction also promotes the 
electrophysiological remodeling observed in AF (16) and accel-
erates atrial ectopy through electrical excitation of cells near the 
pulmonary vein (17). In addition, coronary atherosclerosis may 
injure atrial tissue as result of myocardial ischemia and give rise 
to histological changes, including myocyte hypertrophy, necrosis 
and apoptosis (18,19). These processes may promote atrial 
remodeling with structural, functional, electrical, and metabolic 
consequences that underlie the development of AF (18,19).
The current study demonstrated that rs11552708 [G/A 
(G67R)] of TNFSF13, rs113710653 [C/T (E231K)] of SPATC1L 
and rs11231397 [G/C (R300T)] of SLC22A25 were significantly 
associated with AF in Japanese individuals. The minor T allele 
of rs113710653 and the minor C allele of rs11231397 were 
risk factors for AF, whereas the minor A allele of rs11552708 
was protective against this condition. The rs77538589 [C/T 
(G117R)] SNP of SALL4 also showed a tendency to be associ-
ated to AF, although the association did not achieve statistical 
significance, with the minor T allele representing a risk factor 
for this condition.
The TNFSF13 gene is located at chromosomal 
region 17p13.1 (www.ncbi.nlm.nih.gov/gene/8741) and is 
expressed in various tissues and organs including heart 
muscle (The Human Protein Atlas, www.proteinatlas 
.org/ENSG00000161955-TNFSF13/tissue). TNFSF13 is a 
regulator of the development and function of B cells (20). 
It has been suggested that TNFSF13 has important roles in 
normal immune responses, and also in the development 
of autoimmune and inflammatory diseases. Plasma levels 
of TNFSF13 were reported to be increased in patients with 
multiple sclerosis (21), Sjögren's syndrome (22), systemic lupus 
erythematosus (23) and rheumatoid arthritis (24). The levels of 
TNFSF13 were also demonstrated to be significantly higher 
in the synovial fluid of patients with rheumatoid arthritis than 
in the serum, suggesting that this protein may be produced 
locally at the site of inflammation (25). Previous GWASs iden-
tified TNFSF13 as a susceptibility locus for immunoglobulin A 
nephropathy (26). Chronic vascular inflammation is an impor-
tant feature of atherosclerosis (27), and atherosclerosis was 
previously reported to be associated with increased expression 
of TNFSF13. The plasma levels of TNFSF13 were demon-
strated to be greater in patients with coronary artery disease 
than in healthy controls, and TNFSF13 immunoreactivity was 
Figure 2. Manhattan plot for P-values of allele frequencies in the exome-wide association study of AF. P-values [-log10 (P-values)] on the y-axis are shown 
according to the physical chromosomal position of the corresponding single nucleotide polymorphism on the x‑axis. The SNPs ultimately identified as being 
associated with AF are indicated. AF, atrial fibrillation; SLC22A25, solute carrier family 22 member 25; TNFSF13, TNF superfamily member 13; SALL4, spalt 
like transcription factor 4; SPATC1L, spermatogenesis and centriole associated 1 like.
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Table II. The 122 SNPs significantly associated with atrial fibrillation by exome‑wide association analysis.
  Nucleotide substitution Chromosome:  MAF  P-value 
Gene SNP (amino acid)a Position (%) (allele) Allele OR
N4BP2 rs61748749 T/G (S1353R) 4: 40122170 2.3 <1.0x10-255 0.74
DNAH17 rs690844 A/C (I1742M) 17: 78501838 2.5 8.94x10-255 1.31
HELZ rs184499441 C/T (G1288R) 17: 67114380 1.6 4.40x10-240 1.08
 rs7828656 A/C 8: 11645425 44.8 1.87x10-220 1.1
SLA2 rs221308 T/C 20: 36647995 46.7 4.11x10-218 0.99
SSPO rs55976638 G/T 7: 149832881 4.3 2.99x10-182 1.31
TCEB3B rs2010834 A/C (F254C) 18: 47034504 24.5 2.60x10-141 1.1
FANCL rs149731356 T/C (T224A) 2: 58165745 0.7 7.35x10-130 0.75
PIEZO1 rs143004911 G/A (R333C) 16: 88737957 2.7 5.07x10-122 0.87
TTYH2 rs9899862 C/A (D423E) 17: 74253090 6.3 1.31x10-96 0.86
TUBB3 rs2302898 A/G 16: 89932386 23.5 1.13x10-87 0.87
SLCO6A1 rs17150488 T/C (K381R) 5: 102438751 0.6 3.30x10-81 1.05
GMDS rs9378305 C/T 6: 1703056 41.4 1.20x10-54 0.99
RP1L1 rs79329877 T/C 8: 10622701 9.2 2.05x10-53 1.05
FCMR rs150080259 T/G (S61R) 1: 206902976 1.5 1.07x10-49 1.02
RTKN2 rs7090884 A/G 10: 62202267 33.2 4.97x10-46 1.05
UTP4 rs193164904 A/G (I534V) 16: 69163131 0.2 1.90x10-45 1.58
SNAPC1 rs74810099 T/G (M36R) 14: 61762567 2.8 1.99x10-43 1.02
ALPK2 rs3809977 G/T (P1174H) 18: 58536666 17.2 3.05x10-42 0.93
CSPG4 rs137981794 T/C (D1936G) 15: 75676712 0.4 4.05x10-42 ND
MDN1 rs9294445 A/G (Y3423H) 6: 89692763 7.5 1.15x10-41 0.99
SETD7 rs6814310 C/A 4: 139534374 48.4 1.64x10-41 0.97
PLA2G4E rs4924595 T/C (N400S) 15: 41995408 18.2 1.87x10-35 1.01
KIF7 rs117123311 C/G (S788R) 15: 89642233 3.1 1.03x10-32 1
CTBP2 rs3781411 C/T (R298Q) 10: 125026867 7 1.46x10-30 0.9
GATA2 rs78245253 G/C (A250P) 3: 128485850 4.6 1.37x10-27 0.79
DLGAP1 rs3745051 C/T 18: 3729175 34.4 1.64x10-26 0.86
 rs1711393 T/C 4: 178074088 31 1.70x10-26 1.14
SLAMF7 rs117009784 A/C (R96S) 1: 160750053 5.8 3.86x10-26 1.07
USP32 rs8079220 C/T 17: 60239372 20.5 3.56x10-25 0.91
 rs8011192 T/G 14: 28319412 33.1 8.46x10-25 0.99
IMPDH1 rs201001000 G/A (T369M) 7: 128395003 0.1 3.85x10-24 0.79
ADRA1A rs151273238 G/A (T391M) 8: 26770378 0.2 2.12x10-23 0.71
TNFSF13 rs11552708 G/A (G67R) 17: 7559238 36.6 1.32x10-22 0.54
SLC18A3 rs118107581 A/G (I426V) 10: 49612016 2 1.62x10-22 1.11
NFATC2 rs12479626 T/C (H446R) 20: 51475656 4.7 2.79x10-22 1.06
TENM4 rs3812723 C/T (V396I) 11: 78863031 1.7 1.03x10-21 0.89
EPN1 rs200478642 C/T (P203L) 19: 55689301 0.1 1.52x10-21 0.35
HNRNPC rs17197037 A/G 14: 21257495 29.1 3.26x10-21 0.99
TMX4 rs2076015 T/C (R303G) 20: 7982394 41.1 4.49x10-21 1.16
FOXN4 rs140167217 G/A (S308F) 12: 109281778 0.4 4.51x10-19 1.12
CEP152 rs145138194 G/A (S894F) 15: 48760148 1.2 6.92x10-18 0.73
FREM2 rs114864077 C/T (P128L) 13: 38687727 0.1 1.04x10-17 1.81
CPA6 rs4737845 T/C 8: 67542707 43.3 1.87x10-17 1.04
KIF15 rs146292440 G/A (R1199H) 3: 44843135 0.6 3.33x10-17 0.57
MFSD1 rs3765083 A/G (I230V) 3: 158819654 30.3 4.19x10-17 1.05
BAHD1 rs3743143 A/G (E26G) 15: 40458541 10.5 5.85x10-17 0.99
 rs1395821 A/G 4: 147126398 39.6 6.48x10-17 1.05
BRWD1 rs2183573 G/A (P1511S) 21: 39202379 46 1.11x10-16 1.06
CD69 rs199676648 G/A (R32C) 12: 9756390 0.3 2.93x10-16 0.9
HR rs12675375 C/T (G337D) 8: 22127432 43.4 8.47x10-16 1.02
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Table II. Continued.
  Nucleotide substitution Chromosome:  MAF  P-value 
Gene SNP (amino acid)a Position (%) (allele) Allele OR
SOAT1 rs143616084 G/A (R292Q) 1: 179345008 0.1 6.19x10-15 ND
JMJD1C rs149833441 T/C (K878E) 10: 63208491 1.2 9.49x10-15 1.44
VWDE rs848016 A/G (F142S) 7: 12389177 36.7 1.41x10-14 1.05
VPS13D rs143833298 G/A (R830Q) 1: 12276077 0.8 1.59x10-14 0.86
SPATC1L rs113710653 C/T (E231K) 21: 46161921 1.9 1.60x10-14 5.36
SNX19 rs117834100 C/A (G416C) 11: 130914694 6.9 1.83x10-14 0.89
 rs9854207 A/C 3: 27572825 40.3 3.41x10-14 1.04
ARHGAP8 rs5766113 A/G 22: 44855543 36.8 7.18x10-14 1.03
 rs4407763 G/A 7: 67553705 35.8 1.14x10-13 1.08
SLC22A25 rs11231397 G/C (R300T) 11: 63183749 43.7 1.53x10-13 1.55
XIRP2 rs77219745 G/A (G1839D) 2: 167246908 7 2.89x10-13 0.81
MCM10 rs7905784 A/T (T541S) 10: 13192356 2.2 5.31x10-13 1.05
HIST1H2AC rs198823 G/T 6: 26122705 22.9 1.60x10-12 0.86
 rs10102598 G/A 8: 47178128 37.7 1.61x10-12 0.96
VPS13C rs77555508 G/A (S1798F) 15: 61940726 0.6 2.47x10-12 1.44
ADCY3 rs7586879 C/T 2: 24894108 44.7 1.18x10-11 0.99
CTC1 rs183966301 G/A (A1025V) 17: 8229384 0.2 1.84x10-11 0.56
SALL4 rs77538589 C/T (G117R) 20: 51792134 4.3 2.24x10-11 2.61
ADCY7 rs201661947 G/A (A475T) 16: 50304414 0.2 3.37x10-11 ND
TP53INP1 rs896854 G/A 8: 94948283 30.7 3.76x10-11 0.96
TMEM245 rs2271877 C/T (A314T) 9: 109091132 11.5 8.13x10-11 0.98
FCRL1 rs149740001 A/T (K103I) 1: 157803856 1 8.38x10-11 1.22
SCYL2 rs200554353 T/C (M256T) 12: 100312568 1.6 8.73x10-11 0.36
TMCO3 rs185071949 C/T (P14L) 13: 113495622 0.4 1.97x10-10 1.02
WDR27 rs3734905 C/T 6: 169558886 19.5 3.00x10-10 0.99
NGB rs117207261 C/G (Q60E) 14: 77269238 0.5 3.59x10-10 1.24
 rs6695567 A/G 1: 53163913 43.6 4.89x10-10 1.05
FAP rs151314911 C/T 2: 162173786 2.9 5.26x10-10 1.02
 rs13277113 A/G 8: 11491677 31.9 5.36x10-10 1.01
ACER1 rs72981971 T/C (M74V) 19: 6312279 36.5 5.41x10-10 1
FREM2 rs2496425 T/C (F1070S) 13: 38690553 38.3 7.29x10-10 1.01
ASB13 rs138695721 A/C (V139G) 10: 5649071 0.6 7.67x10-10 1.09
 rs10943716 T/C 6: 80543356 40.2 1.05x10-9 1.05
CCDC168 rs1449707 A/G (I3015T) 13: 102741653 44.4 1.82x10-9 0.98
ADGRV1 rs2366928 A/G (K3471E) 5: 90728918 17.9 2.17x10-9 0.97
MDN1 rs115931523 G/A (T3130M) 6: 89695987 0.2 2.44x10-9 1.58
CD96 rs140727933 A/G (Y11C) 3: 111542280 0.2 2.63x10-9 1.16
 rs4965121 G/C 15: 97975562 8.5 2.69x10-9 0.97
KNL1 rs11858113 T/C (M598T) 15: 40621979 27.4 3.29x10-9 0.99
OR4X2 rs7120775 C/G (Y27*) 11: 48245184 16.9 3.65x10-9 1.05
TRPM2 rs144412484 A/G (E450G) 21: 44390934 0.4 3.68x10-9 0.82
MGAT5 rs66523341 C/T 2: 134364804 37 4.17x10-9 0.93
GCOM1 rs4774980 G/A 15: 57691677 6 5.40x10-9 0.98
CSMD2 rs1874045 T/C (K2096R) 1: 33605925 45.1 7.56x10-9 1.08
ADAT1 rs200524721 G/C (Q167H) 16: 75612785 0.3 8.75x10-9 1.12
 rs4420065 T/C 1: 65695778 13.1 1.52x10-8 1.02
NLRX1 rs149129258 C/A (P262Q) 11: 119174034 0.5 2.31x10-8 0.99
DNAAF3 rs890871 A/G (L280P) 19: 55160687 25.2 3.01x10-8 0.98
ZNF25 rs150582814 T/C (Y202C) 10: 37952893 0.1 3.01x10-8 ND
CMYA5 rs62621915 C/T (L1038F) 5: 79731877 49.3 5.62x10-8 0.93
SYDE2 rs141587551 C/A (D173Y) 1: 85200480 6.6 6.20x10-8 1.03
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detected in aggregated platelets within the ruptured plaque 
of patients with myocardial infarction (28). Pronounced 
TNFSF13 immunostaining was also observed in macrophages 
from carotid plaques (28). The current study demonstrated 
that rs11552708 [G/A (G67R)] of TNFSF13 was significantly 
associated with AF, with the minor A allele being protec-
tive against this condition. Chronic vascular inflammation, 
atherosclerosis, endothelial dysfunction and subsequent atrial 
remodeling are important in the pathogenesis of AF. Given 
that TNFSF13 is implicated in vascular inflammation and 
atherosclerosis (28), the association of TNFSF13 rs11552708 
[G/A (G67R)] with AF may be attributable to the effect of this 
gene on atrial remodeling.
The SPATC1L gene is located at chromosomal region 
21q22.3 (www.ncbi.nlm.nih.gov/gene/84221) and is 
expressed in various tissues and organs including heart 
muscle (The Human Protein Atlas, www.proteinatlas 
.org/ENSG00000160284-SPATC1L/tissue). SPATC1L 
is distributed in the cytoplasm, nucleus and perinuclear 
region of cells, and it translocates to sites of cell-cell junc-
tions in response to cell stimulation with neurokinin A (29). 
Expression of SPATC1L modulates the response of human 
cells to N-methyl-N'-nitro-N-nitrosoguanidine, suggesting that 
the encoded protein may have a role in protecting cells from 
cell death induced by this DNA-damaging agent (30). The 
current study demonstrated that rs113710653 [C/T (E231K)] 
of SPATC1L was significantly associated with AF, with the 
minor T allele representing a risk factor for this condition, 
although the underlying molecular mechanism of this associa-
tion remains unclear.
The SLC22A25 gene is located at chromosomal region 
11q12.3 (www.ncbi.nlm.nih.gov/gene/387601) and is abun-
dantly expressed in the liver (The Human Protein Atlas, 
www.proteinatlas.org/ENSG00000196600-SLC22A25/tissue). 
SLC22 is a large family of transmembrane organic cation 
and anion transporter proteins expressed predominantly 
in kidney and liver that mediate the uptake and excretion of 
environmental toxins, endogenous substances and drugs in 
the body (31). The results of the present study indicated that 
rs11231397 [G/C (R300T)] of SLC22A25 was significantly 
associated with AF, with the minor C allele representing a risk 
factor for this condition, although the functional relevance of 
this association remains unknown.
The SALL4 gene is located at chromosomal region 
20q13.2 (www.ncbi.nlm.nih.gov/gene/57167) and is 
expressed in various tissues and organs including heart 
muscle (The Human Protein Atlas, www.proteinatlas 
.org/ENSG00000101115-SALL4/tissue). Mutations in SALL4 
have been identified as a cause of Okihiro syndrome, which is 
characterized by developmental defects in limbs and multiple 
organs including the heart (32,33). Expression of SALL4 was 
detected in the left ventricular myocardium and interven-
tricular septum of the mouse heart at embryonic day 10.5 (34). 
The current study demonstrated that rs77538589 [C/T (G117R)] 
Table II. Continued.
  Nucleotide substitution Chromosome:  MAF  P-value 
Gene SNP (amino acid)a Position (%) (allele) Allele OR
SLC15A5 rs3915247 C/T 12: 16247679 47.6 7.01x10-8 0.97
CDC42BPG rs3741395 T/C (Q1135R) 11: 64830034 5.6 8.31x10-8 1.11
 rs8030485 G/A 15: 79116590 35.2 9.03x10-8 0.98
 rs2564486 G/T 18: 59579061 12.9 9.24x10-8 1.05
SLC4A4 rs1062677 A/C (I1074L) 4: 71567828 6.1 1.20x10-7 0.91
STEAP1B rs17364464 A/G 7: 22474434 12.2 2.03x10-7 0.99
KLF17 rs11210969 T/A (I35N) 1: 44129375 22.5 2.83x10-7 1.11
ADAMTS13 rs78977446 C/T (S903L) 9: 133445796 4.5 3.10x10-7 1.24
ZNF879 rs17078988 A/G (T112A) 5: 179032282 33.8 4.42x10-7 1.01
 rs1464833 T/C 7: 125475608 10.2 4.58x10-7 1.01
PKD1L1 rs10951936 A/T 7: 47882084 21 7.76x10-7 1.01
SNX32 rs200684568 G/A (G179R) 11: 65850787 0.5 9.00x10-7 0.56
NTF3 rs6332 G/A 12: 5494466 41.8 9.12x10-7 1.09
EFHD1 rs4072149 T/C 2: 232643967 36.7 9.18x10-7 1.01
URB2 rs3811473 G/T (G778V) 1: 229636946 15.8 9.48x10-7 1.05
CCDC71 rs4955419 A/T (Q317L) 3: 49163259 4.6 9.91x10-7 1.13
 rs543588 T/G 13: 30096848 31.4 1.01x10-6 0.9
TRIM40 rs757259 G/A (E244K) 6: 30147765 16 1.06x10-6 1.12
 rs3129264 T/C 6: 33133825 8.3 1.07x10-6 0.8
SEMA6A rs12516652 G/T (D567E) 5: 116475552 1.9 1.14x10-6 1.2
Allele frequencies were analyzed with Fisher's exact test. P<1.21x10-6 was considered to indicate a significant association. aMajor allele/minor 
allele. SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio; ND, not determined. SNPs without gene names 
are not located within the genes.
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of SALL4 tended to be associated with AF, with the minor 
T allele representing a risk factor for this condition. Given that 
SALL4 may have an important role in heart development, the 
association of rs77538589 of SALL4 with AF may reflect an 
effect of this gene on atrial structure or electrical function.
A meta-analysis of GWASs for AF (10) identified 10 
SNPs (rs6666258 of potassium calcium‑activated channel 
subfamily N member 3, rs3903239 of paired related homeobox 
1, rs6817105 of paired like homeodomain 2, rs2040862 of Wnt 
family member 8A, rs3807989 of caveolin 1, rs10821415 of 
chromosome 9 open reading frame 3, rs10824026 of synapto‑
podin 2 like, rs1152591 of spectrin repeat containing nuclear 
envelope protein 2, rs7164883 of hyperpolarization activated 
cyclic nucleotide gated potassium channel 4 and rs2106261 of 
zinc finger homeobox 3) as susceptibility loci for this condi-
tion. The MAF of these SNPs ranged from 13.1‑44.7% and the 
odds ratio from 0.87-1.64 (10). In the current study, four novel 
loci that may confer susceptibility to AF were identified, with 
the allele odds ratio (MAF, %) of rs11552708 of TNFSF13, 
rs113710653 of SPATC1L, rs11231397 of SLC22A25 and 
rs77538589 of SALL4 being 0.54 (36.6%), 5.36 (1.9%), 1.55 
(43.7%) and 2.61 (4.3%), respectively. Both rs11552708 of 
TNFSF13 and rs11231397 of SLC22A25 were thus common 
variants with a low effect size, whereas rs113710653 of 
SPATC1L and rs77538589 of SALL4 were low-frequency vari-
ants with a moderate to high effect size.
There are several limitations to the present study: i) Given 
that the results of the study were not replicated, the findings 
will require validation in other independent subject panels 
or other ethnic groups; ii) it is possible that rs11552708 of 
TNFSF13, rs113710653 of SPATC1L, rs11231397 of SLC22A25 
or rs77538589 of SALL4 is in linkage disequilibrium with 
other polymorphisms in the same gene or other nearby genes 
that are actually responsible for the development of AF; and 
iii) the functional relevance of these SNPs to the pathogenesis 
of AF remains to be elucidated.
In conclusion, rs11552708 of TNFSF13, rs113710653 
of SPATC1L, rs11231397 of SLC22A25, and rs77538589 
of SALL4 may be susceptibility loci for AF in Japanese 
individuals. Determination of genotypes of these SNPs may 
prove informative for assessment of the genetic risk for AF in 
Japanese individuals.
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